116 results about "Fasting glucose" patented technology

The disclosed methods and compositions for reducing cardiovascular risk factors in mammals generally includes using genistein to modulate various inflammatory and cardiovascular risk markers including: homocysteine, C-reactive protein, fibrinogen, sex hormone-binding globulin, fasting glucose, insulin, insulin resistance, and osteoprotegerin.

The present invention relates to the administration of compositions comprising an antiestrogen, preferably trans-clomiphene, for treating metabolic syndrome in a subject. The invention is also directed to methods for reducing fasting glucose levels in a subject by administering a composition comprising an antiestrogen, preferably trans-clomiphene.

Methods of treating diseases such as diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA_1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof. Drug products including a bile acid sequestrant and two or more additional compounds selected from the group consisting of a biguanide, a sulfonylurea and insulin, or pharmaceutically acceptable salts thereof, in combination are also disclosed.

A method, system and computer readable medium for tracking changes in average glycemia in diabetes is based on a conceptually new approach to the retrieval of SMBG data. Using the understanding of HbA1c fluctuation as the measurable effect of the action of an underlying dynamical system, SMBG provides occasional glimpses at the state of this system and, using these measurements, the hidden underlying system trajectory can be reconstructed for individual diabetes patients. Using compartmental modeling a new two-step algorithm is provided that includes: (i) real-time estimate of HbA1c from fasting glucose readings, updated with any new incoming fasting SMBG data point(s), and (ii) initialization and calibration of the estimated HbA1c trace with daily SMBG profiles obtained periodically. The estimation of these profiles includes a factorial model capturing daily BG variability within two latent factors.

The invention relates to a glycogen phosphorylase inhibitor cholic acid derivative, a preparation method thereof and a pharmaceutical composition containing the same. The glycogen phosphorylase inhibitor cholic acid derivative is a liver-targeted pro-drug for glycogen phosphorylase; compared with a glycogen phosphorylase inhibitor, the concentration of the glycogen phosphorylase inhibitor in a liver can be increased after the glycogen phosphorylase inhibitor cholic acid derivative is taken orally, so that the glycogen phosphorylase inhibitor cholic acid derivative can serve as a preferred drug for lowering blood sugar, particularly for treating impaired fasting glucose. The compound can be used for preventing and treating diabetes and complications thereof, hyperlipidemia, obesity, high-glucagon disease, insulin resistance, impaired fasting glucose, hypertension and complications thereof, atherosclerosis, metabolic syndrome or tumor.

The invention discloses an application of lactobacillus rhamnosus CCFM1060 in preparation of functional microbial agents, foods and/or medicines. The lactobacillus rhamnosus CCFM1060 can tolerate thegastrointestinal environment of the human body, significantly improve fasting blood glucose rise and abnormal oral glucose tolerance of type 2 diabetics caused by high fat diet and STZ injection, reduce the area under the curve during glucose tolerance drug administration, and relieve insulin resistance; remarkably improve the increase of total cholesterol content and the increase of low-density lipoprotein cholesterol in serum of type 2 diabetics caused by high-fat diet and STZ injection; obviously relieve the inflammatory state of the liver; and significantly reduce pancreatic and liver pathological injuries caused by high-fat diet and STZ injection. The lactobacillus rhamnosus CCFM1060 has relatively strong adsorption capacity on perfluorooctanoic acid (PFOA), and has the capacity of relieving the toxicity of the PFOA.

The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I)

The invention is directed to methods of using Chlorella protothecoides microalgal biomass in the treatment of individuals having impaired glucose metabolism. In some cases, the patient has impaired fasting glucose, impaired glucose tolerance, or diabetes. In some methods, algal biomass is used to reduce blood glucose and/or body fat in a subject, or to increase the relative abundance of beneficial gut microflora in a subject. In preferred embodiments, the biomass is derived from Chlorella protothecoides cultures grown heterotrophically in which the algal cells comprise at least 15% algal oil by dry weight.

Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

The invention provides a method for using OCT human tissue scan data for tracking a scan structure in depth, follow change in structure position within an OCT scan from, for example, fasting glucose level to peak glucose level and back down again, and relate the structure position change to analyte concentration. In the preferred embodiment, the analyte of interest is glucose concentration and the target of interest is living human skin. A hyaluronic acid based mechanism is suggested for dermis thickness. Alternate embodiments of the method are presented, including curve fitting of topographic regions corresponding to trackable target features.

The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula:

where R₁, R₂, R_2′, R₃, R₄, X₁, X₂, X₃, X₄, Q, and n are described herein.

The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

The invention relates to an azo bond contained glycogen phosphorylase inhibitor cholic acid derivative, a preparation method thereof and a pharmaceutical composition containing the same. The azo bond contained glycogen phosphorylase inhibitor cholic acid derivative is a liver-targeted pro-drug for glycogen phosphorylase; compared with a glycogen phosphorylase inhibitor, the concentration of the glycogen phosphorylase inhibitor in a liver can be increased after the glycogen phosphorylase inhibitor cholic acid derivative is taken orally, so that the glycogen phosphorylase inhibitor cholic acid derivative can serve as a preferred drug for lowering blood sugar, particularly for treating impaired fasting glucose. The compound can be used for preventing and treating diabetes and complications thereof, hyperlipidemia, obesity, high-glucagon disease, insulin resistance, impaired fasting glucose, hypertension and complications thereof, atherosclerosis, metabolic syndrome or tumor.

The invention relates to a novel application of metabolites, namely galactose, 1, 5-sorbitan, N-acetyl glucosamine and 2-hydroxybutyric acid, in fasting serum as combined markers in preparation of a kit for rapidly diagnosing diabetic patients in subjects. Whether a subject suffers from diabetes mellitus or not is judged by detecting the concentrations of the four metabolites in an empty serum sample of the subject, the combined marker variable P is calculated based on a binary logistic regression equation and an intercept point value is judged, and whether the subject suffers from diabetes or not is judged. The kit can realize high-sensitivity and high-efficiency detection, and the small molecule metabolites involved in the invention have the characteristics of low detection cost and good repeatability. The kit can be applied to auxiliary rapid screening of diabetes people, has the characteristic of mutual complementation with the traditional clinical index fasting blood glucose, and has a relatively good application prospect.